Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Karuna Pharmaceuticals Inc.

Latest From Ucyclyd Pharma Inc.

Betta IPO Tells Tale Of Shifting Strategy By China Innovators

As a national innovation darling, Betta Pharma is gearing up to a much-hyped public listing in China. Combing through its 300-plus page prospectus, however, unveils a different Betta striving to diversify amid looming competition and price pressure.

BioPharmaceutical China

Hyperion Pricing On Ravicti Will Test Premium For Convenience In Orphan Market

Ravicti’s price tag is $250,000 to $290,000 per year while the upper WAC price for Valeant’s competing product Buphenyl is roughly $240,000 at the maximum dose; Hyperion has option to acquire Buphenyl.

BioPharmaceutical United States

Hyperion’s Orphan Drug Ravicti Clears FDA; Postmarket Studies Required

Hyperion will launch the drug for treatment of urea cycle disorders in April, and the firm will need to plan a 10-year registry for patients.

BioPharmaceutical Regulation

Contract Research Firm CMIC Joins Pharma Market With One Orphan Drug And More On The Way

Novartis and Novo Nordisk receive first global approvals for compounds in Japan in recent slate of approvals, along with a wave of government-subsidized orphan drugs.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Karuna Pharmaceuticals Inc.
  • Senior Management
  • Edmund Harrigan, PhD, CEO
  • Contact Info
  • Karuna Pharmaceuticals Inc.
    Phone: (617) 482-2333
    500 Boylston St.
    Ste. 1600
    Boston, MA 02116